



PerkinElmer Announces Strategic Acquisition of Arnel Inc.

WALTHAM, Mass., Dec 03, 2008 (BUSINESS WIRE) --PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and their environment, today announced the acquisition of Arnel Inc., a recognized leader in custom engineered solutions for gas chromatography applications in the petrochemical, food and beverage, and industrial hygiene markets. The acquisition is an important strategic initiative to expand PerkinElmer's chromatography portfolio and strengthen its application-focused expertise to best serve the biofuels and hydrocarbon processing industries.

This acquisition is a natural extension of PerkinElmer's and Arnel's 18 year relationship during which Arnel served as PerkinElmer's exclusive supplier of gas sampling valve solutions. With the completion of this transaction, PerkinElmer expects to accelerate its development and expand its portfolio of application-focused measurement systems tailored for the biofuels, food and beverage, industrial hygiene, and hydrocarbon processing markets.

"PerkinElmer has a deep understanding of our customers' specific industry related challenges, whether these customers are in the pharmaceutical, consumer, or food quality industries," notes Richard Begley, Ph.D., president, PerkinElmer Analytical Sciences. "Our acquisition of Arnel brings us greater expertise in the hydrocarbon processing industry through differentiated technology in gas chromatography. In addition, we believe that combining Arnel's technologies with PerkinElmer's chromatography capabilities will help our customers develop cleaner, petroleum based products to help reduce their impact on the environment as well as assist in manufacturing more cost effective petroleum products."

Through this acquisition, PerkinElmer continues its ability to provide standard and custom petroleum tailored solutions based upon PerkinElmer's gas chromatography platform. These analyzers include the widest range of refinery/light hydrocarbon gas analyzers (RGA) and natural gas analyzers (NGA) in the industry.

"Arnel is excited by the opportunity to become a part of PerkinElmer," said Clarence Wentzel, president, Arnel Inc. "Throughout our 18 year relationship, we have always worked very closely with PerkinElmer to ensure we brought the best solutions to our customers. This transaction further solidifies that commitment to our customers and positions the combined organization for further market expansion."

For additional information related to PerkinElmer's gas chromatography solutions, please call 800-762-4000.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of \$1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) markets into which we sell our products decline or do not grow as anticipated; (4) our failure to adequately protect our intellectual property; (5) the loss of any of our licenses or licensed rights; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to produce an adequate quantity of products to meet our customers' demands; (11) the manufacture and sale of products may expose us to product liability claims; significant disruption in third-party package delivery and import/export services or significant increases in prices for those

services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to produce an adequate quantity of products to meet our customers' demands; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with health care industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) restrictions in our credit agreements; (18) our ability to realize the full value of our intangible assets; and (19) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: PerkinElmer, Inc.

Investor Relations:

PerkinElmer, Inc.

Dave C. Francisco

781-663-5677

or

Media Contact:

PerkinElmer, Inc.

Stephanie R. Wasco

781-663-5701

stephanie.wasco@perkinelmer.com

or

Additional Media Contact:

PerkinElmer Analytical Sciences

Chris P. Tessier

413-208-6872

christopher.tessier@perkinelmer.com

Copyright Business Wire 2008

News Provided by COMTEX